AMENDMENT

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 3, lines 5-8, and replace it with the following paragraph:

In further embodiments, X_1 is a valine or a conservatively modified variant thereof or X_2 is a glutamine or a conservatively modified variant thereof. In a preferred embodiment, the polypeptide will comprise the contiguous amino acid sequence DVCQD **(SEQ ID NO: 28)**.

Please delete the paragraph on page 3, lines 16-26, and replace it with the following paragraph:

In still another embodiment, the isolated polypeptide comprises R-DVCQD-R' **(SEQ ID NO: 44)**; wherein R is from 0 to about 6 contiguous amino acids; and wherein R' is from 0 to about 59 contiguous amino acids. In a preferred embodiment, the polypeptide comprises R-XDVCQD-R' **(SEQ ID NO: 45)**; wherein R is selected from the group consisting of Aa_1-Aa_2-Aa_3-Aa_4-Aa_5, Aa_2-Aa_3-Aa_4-Aa_5, Aa_3-Aa_4-Aa_5, Aa_4-Aa_5 and Aa_5. Aa_1, Aa_2, Aa_3, Aa_4 and Aa_5 are selected from the group consisting of amino acids; X is selected from the group consisting of G, A, S and T; and wherein R' is from 0 to about 59 contiguous amino acids. In a more preferred embodiment, Aa1 is a glutamine or a conservative substitution thereof, Aa_2 in a proline or a conservative substitution thereof, Aa_3 in a lysine or a conservative substitution thereof, Aa_4 in an aspartic acid or a conservative substitution thereof, or Aa_5 in a asparagine or a conservative substitution thereof.

Please delete the paragraph on page 4, lines 3-4, and replace it with the following paragraph:

A3

In a most preferred embodiment, the isolated polypeptide has the amino acid sequence GDVCQDCIQMV **(SEQ ID NO: 19)**.

Please delete the paragraph on page 6, lines 1-2, and replace it with the following paragraph:

A4

Figure 1E: Activity of N-terminus pentapeptide (DVCQ~~C~~**D**, **SEQ ID NO 28**). Only endothelial cells show dose dependent growth inhibition.

Please delete Table 8, on pages 55-56, and replace it with the following Table:

Table 8: Saposin B Peptides Activity Summary

A5

Name	Core Lab code/group	Seq ID No.	Sequence	IC50 (mM)Activity in KS Y-1
	internal peptide scan			
G1-V11	20PG	19	GDVCQDCIQMV	4.9
Q9-F15	2PG	43	QMVTDIQTQVRTNSTF	14
S23-R39	3PG	15	STFVQALVEHVKEECDR	22
C37-S53	4PG	42	CDRLGPGMAKICKNYIS	9.7
Y51-P68	5PG	17	YISQYSEIAIQMMMHMQP	20
Q67-E80	36PG	41	QPKEICALVGFCDEVK	14
	Bisection of 20PG			
G1-Q5	23PG	22	GDVCQ	49.4
D6-V12	24PG	23	DCIQMV	57.3
	C-terminal deletions			
D2-M10	25PG	24	DVCQDCIQM	16.2
D2-Q9	26PG	25	DVCQDCIQ	16.6
D2-I8	27PG	26	DVCQDCI	20
D2-C7	28PG	27	DVCQDC	19
D2-D6	29PG	~~31~~ **28**	DVCQD	11.8
	N-terminal deletions			
D2-V11	22PG	21	DVCQDCIQMV	4.4
V3-V11	30PG	29	VCQDCIQMV	11.9

Name	Core Lab code/group	Seq ID No.	Sequence	IC50 (mM)Activity in KS Y-1
C4-V11	31PG	30	CQDCIQMV	13.2
Q5-V11	32PG	31	QDCIQMV	16.6
	C-S mutations			
G1-(S4,S7)-V11	21PG	20	GDVSQDSIQMV	>400
G1-(S4)-V11	33PG	32	GDVSQDCIQMV	18
G1-(S7)-V11	34PG	33	GDVCQDSIQMV	7.8
G1-(S4)-D6	35PG	34	GDVSQD	40
	V3 and Q5 mutations			
D2-(A3)-D6	37PG	35	DACQD	42.9
D2-(I3)-D6	38PG	36	DICQD	34.6
D2-(L3)-D6	39PG	37	DLCQD	39.8
D2-(S5)-D6	40PG	38	DVCSD	25.5
D2-(E5)-D6	41PG	39	DVCED	26.3
D2-(D5)-D6	42PG	40	DVCDD	12.2

In vivo results for experiments similar to those described in Example 6 demonstrate that the pentapeptide DVCQD (SEQ ID NO 28) was active *in vivo* (*see* Figure 6).